Key advances in gut microbiome research during 2025

12 Jan 2026

by GMFH Editing Team

2025 has been a productive year in gut microbiome research, spanning metabolic health, neurogastroenterology, immune modulation, and precision nutrition. In this ‘Year in Review’ article, the GMFH editing team describes their pick of the top GMFH-covered advances in 2025, outlining their impact in the clinical setting and implications for current and future research.

Crohn’s disease is an immune-mediated disease without a cure. While current guideline-based therapies are immune-directed therapies (small molecules and biologics), recent advances in understanding how the gut microbiome changes precede and drive disease offer potential for developing personalized therapeutics.

Dietary fibers, known to regulate intestinal inflammation and gut barrier functions, have been avoided by patients with inflammatory bowel diseases (IBD) to avoid flare-ups. However, recent findings suggest that if fiber type, patient immunological condition, and the fermentative ability of the gut microbiota are taken into account, they could be beneficial and prevent relapses.

Differences in the gut microbiota in patients with IBD compared to healthy controls suggest that probiotics may be of help. This article takes an in-depth look into the rationale of using probiotics for IBD and summarizes the evidence from recent clinical guidelines for the use of probiotics in Crohn’s disease, ulcerative colitis and pouchitis.

Study identifies a role for bacterial proteases in Crohn’s disease

26 Jun 2023

by Amber Hann, Heather Galipeau

Inflammatory bowel disease is a chronic remitting and relapsing condition that causes severe inflammation of the intestines and disabling bowel symptoms. It affects millions of lives globally, and although alterations in the gut microbiome have been associated with IBD, precise mechanisms remain incompletely understood. New research from McMaster University now implicates bacterial proteases in Crohn’s disease.

Scientists have discovered a fungus that delays wound healing in mice and is enriched in inflamed tissue from patients with Crohn’s disease. The findings, coupled with the discovery of an engineered yeast that suppresses inflammation in a mouse model of colitis, highlights the potential of studying fungi-host interactions in IBD.

Go to Top